We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+3.56%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.89B
AUM Growth
+$345M
(+14%)
Cap. Flow
-$69.9M
Cap. Flow
% of AUM
-2.42%
Top 10 Holdings %
Top 10 Hldgs %
30.33%
Holding
133
New
31
Increased
28
Reduced
22
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Q32 Bio
QTTB
|
+$97.6M |
| 2 |
Centene
CNC
|
+$61.3M |
| 3 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$51.5M |
| 4 |
MLNT
Melinta Therapeutics, Inc. Common Stock
MLNT
|
+$41.1M |
| 5 |
CVS Health
CVS
|
+$39.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DexCom
DXCM
|
+$52.4M |
| 2 |
Glaukos
GKOS
|
+$51.5M |
| 3 |
Insulet
PODD
|
+$41.5M |
| 4 |
McKesson
MCK
|
+$38.1M |
| 5 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
+$35.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 74.89% |
| 2 | Financials | 1.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MNK
1
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $125M | 4.33% |
8,621,383
+2,855,383
| +50% | +$51.5M |
|
2
Viatris
VTRS
$20.1B
| $105M | 3.63% |
2,548,111
+44,500
| +2% | +$1.9M |
|
|
3
Q32 Bio
QTTB
$255M
| $97.7M | 3.39% |
+290,391
| New | +$97.6M |
|
|
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $93.9M | 3.25% |
6,609,894
+268,000
| +4% | +$3.96M |
|
|
AVXS
5
DELISTED
AveXis, Inc. Common Stock
AVXS
| $93.4M | 3.24% |
755,798
| – | – |
|
6
AnaptysBio
ANAB
$1.72B
| $82.7M | 2.86% |
794,338
-18,146
| -2% | -$2.05M |
|
|
DBVT
7
DBV Technologies
DBVT
$870M
| $66.9M | 2.32% |
290,000
+79,482
| +38% | +$18.8M |
|
|
8
Centene
CNC
$32.8B
| $62.8M | 2.18% |
+1,176,000
| New | +$61.3M |
|
|
MYOK
9
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $52.2M | 1.81% |
1,068,680
+68,000
| +7% | +$3.53M |
|
|
10
Glaukos
GKOS
$9.21B
| $50.7M | 1.76% |
1,643,031
-1,700,014
| -51% | -$51.5M |
|
|
11
DexCom
DXCM
$29.6B
| $48.1M | 1.67% |
2,596,000
-3,540,844
| -58% | -$52.4M |
|
12
Aclaris Therapeutics
ACRS
$793M
| $48.1M | 1.67% |
2,745,705
+512,289
| +23% | +$10.9M |
|
|
LCI
13
DELISTED
Lannett Company, Inc.
LCI
| $44M | 1.52% |
685,269
+5,947
| +0.9% | +$458K |
|
14
Elevance Health
ELV
$80.9B
| $42M | 1.45% |
191,000
+61,000
| +47% | +$14.3M |
|
|
BOLD
15
DELISTED
Audentes Therapeutics, Inc
BOLD
| $41.6M | 1.44% |
1,384,470
+193,954
| +16% | +$6.57M |
|
16
Editas Medicine
EDIT
$457M
| $38.4M | 1.33% |
1,158,841
-550,559
| -32% | -$19.6M |
|
|
17
CALL
CVS Health
CVS
$137B
| $35.3M | 1.22% |
+566,800
| New | +$40.7M |
|
18
BioCryst Pharmaceuticals
BCRX
$2.36B
| $35.1M | 1.22% |
7,366,460
+153,067
| +2% | +$786K |
|
|
BPMC
19
DELISTED
Blueprint Medicines
BPMC
| $34.8M | 1.2% |
378,950
-17,050
| -4% | -$1.47M |
|
|
20
CVS Health
CVS
$137B
| $34.2M | 1.19% |
+550,000
| New | +$39.5M |
|
|
XENT
21
DELISTED
Intersect ENT, Inc
XENT
| $32.7M | 1.13% |
832,500
-635,841
| -43% | -$23.2M |
|
22
DaVita
DVA
$15.2B
| $32.1M | 1.11% |
486,427
+61,427
| +14% | +$4.51M |
|
|
SEM
23
DELISTED
Select Medical
SEM
| $32.1M | 1.11% |
3,448,448
| – | – |
|
24
GSK
GSK
$104B
| $31.6M | 1.1% |
+648,000
| New | +$30.2M |
|
25
Ascendis Pharma A/S
ASND
$17.1B
| $31.6M | 1.09% |
482,467
-306,533
| -39% | -$17.2M |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q1 2018 Portfolio in Review
As of Q1 2018, Deerfield Management held 133 positions worth $2.89B, up 14% from $2.54B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Deerfield Management's Q1 2018 filing shows 31 new, 28 increased, 22 reduced and 15 closed positions. Its largest new stake was Q32 Bio: 290,391 shares worth $97.7M. The largest sale was DexCom, an estimated $52.4M.
By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 79% a quarter earlier, followed by Financials.
- Deerfield Management's largest Q1 2018 buy was Q32 Bio: 290,391 shares worth $97.7M.
- Deerfield Management added most to MALLINCKRODT PUBLIC LIMITED COMPANY in Q1 2018, an estimated $51.5M increase.
- Deerfield Management's biggest Q1 2018 reduction was DexCom, cutting an estimated $52.4M.
- Deerfield Management fully exited Revance Therapeutics, Inc. in Q1 2018, selling an estimated $35.8M.
- Deerfield Management's ten largest holdings make up 30% of its $2.89B portfolio in Q1 2018.
- Deerfield Management opened 31 new positions and closed 15 in Q1 2018.
- Deerfield Management's portfolio value rose 14% quarter-over-quarter to $2.89B.
Based on Deerfield Management's 13F filing for Q1 2018, filed 15 May 2018.